Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients

J.E. Arends, J.T.M. van der Meer, D. Posthouwer, W. Kortmann, K. Brinkman, S. van Assen, C. Smit, M. van der Valk, M. van der Ende, J. Schinkel, P. Reiss, C. Richter, A.I.M. Hoepelman, the Stichting HIV Monitoring/Nederlandse Vereniging van HIV Behandelaren Hepatitis Working Group, the ATHENA national observational HIV cohort

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)324-330
JournalNetherlands Journal of Medicine
Volume73
Issue number7
Publication statusPublished - 1 Jan 2015

Cite this

Arends, J. E., van der Meer, J. T. M., Posthouwer, D., Kortmann, W., Brinkman, K., van Assen, S., Smit, C., van der Valk, M., van der Ende, M., Schinkel, J., Reiss, P., Richter, C., Hoepelman, A. I. M., Stichting HIV Monitoring/Nederlandse Vereniging van HIV Behandelaren Hepatitis Working Group, T., & ATHENA national observational HIV cohort, T. (2015). Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. Netherlands Journal of Medicine, 73(7), 324-330. http://www.njmonline.nl/getpdf.php?id=1606